IB McInnes, PJ Mease, CT Ritchlin,
P Rahman… - …, 2017 - academic.oup.com
Objectives To assess long-term efficacy, safety and tolerability of secukinumab up to 104
weeks in patients with active PsA. Methods Patients with PsA (n= 397) were randomized to …